Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sensor-Embedded Abilify Resubmitted to FDA
May 25, 2017
- Ninlaro Makes Japan Debut, Mundesine Now Also Available
May 25, 2017
- FY2016 Sales Dip for 27 Japan Makers, Second-Tier/Mid-Sized Firms Fare Well: Jiho Tally
May 24, 2017
- 4 Major Distributors’ Wholesale Biz Sinks on Hep C Pullback, Price Revision
May 23, 2017
- Lantus XR Shows Efficacy in Japan Outcome Study: Interim Report
May 23, 2017
- EMA Accepts Application for Fujifilm Kyowa Kirin’s Humira Biosimilar
May 23, 2017
- Ethical Drug Sales Down 4.4% in March: Crecon
May 22, 2017
- Japan NDA Filed for Januvia-Suglat Combination
May 22, 2017
- MHLW OKs Xalkori for ROS1-Positive NSCLC; Zosyn, Kyprolis for Add’l Use
May 19, 2017
- Ogeda Acquisition Completed: Astellas
May 18, 2017
- Opdivo Ranks 2nd in FY2016 Japan Sales Ranking after Harvoni: QuintilesIMS
May 17, 2017
- Aspen Japan to Expand Detailing System with Business Transfer from AZ
May 17, 2017
- Otsuka Gets Japan Rights to Teva’s Migraine Med
May 16, 2017
- Fujifilm, FunPep Join Hands to Create Middle-Molecule Antiviral for HPV
May 16, 2017
- Otsuka to Build Its 6th Drug Factory in Japan, Launch Slated for 2020
May 16, 2017
- Otsuka, Hiroshima Univ. Spinout to Collaborate on CNS Cell Therapies
May 16, 2017
- Seikagaku, Ono to Link Up on Osteoarthritis Treatment
May 16, 2017
- Takeda to Split Part of Research Biz Into New Subsidiary
May 16, 2017
- Suzuken Embarking on Organizational Reforms to Eliminate “High-Cost Structure,” Improve SGA Cost Ratio
May 16, 2017
- Kyorin Poised to Weather Kipres Cliff with Consecutive Drug Launches: President
May 15, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…